A Patient With Graves’ Disease And Thyroid-Associated Orbitopathy Undergoing Radioactive Iodine in Dr. Soetomo General Academic Hospital, Surabaya

• Main Authors: Rizki Adrian Hakim, -, Stepanus Massora, -, Delfitri Lutfi, NIDN. 0027068005, Hermina Novida, -
• Format: Article PeerReviewed
• Language: English; English; English
• Published: Faculty of Medicine Universitas Airlangga 2021
• Subjects: R5-920 Medicine (General)
• Online Access: https://repository.unair.ac.id/127269/1/C-23%20Artikel.pdf; https://repository.unair.ac.id/127269/2/C-23%20karil.pdf; https://repository.unair.ac.id/127269/3/C-23%20turnitin.pdf; https://repository.unair.ac.id/127269/; https://www.e-journal.unair.ac.id/BHSJ/article/view/26914; http://dx.doi.org/10.20473/bhsj.v4i1.26914
• Institution: Universitas Airlangga

Graves’ Disease (GD) is the most common etiology of thyrotoxicosis, followed by toxic multinodular goiter and toxic adenoma. GD can be managed with anti-thyroid drugs (ATDs), surgery, or radioactive iodine (RAI). Thyroid-associated orbitopathy (TAO) or Graves’ Ophthalmopathy (GO) affects 25%-50% pat...